Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 12
Summary
- Conditions
- Breast Cancer
- Breast Carcinoma
- Malignant Neoplasm of Breast
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02204098
- Collaborators
- Rising Tide Foundation
- United States Department of Defense
- Investigators
- Principal Investigator: William Gillanders, M.D. Washington University School of Medicine